Innovair

Formoterol fumarate dihydrate / beclometasone dipropionate anhydrous, the active ingredient in Innovair, is an inhaled corticosteroid/long‑acting β2‑adrenergic agonist (ICS/LABA) presented as an inhalation aerosol (metered‑dose inhaler) for inhalation use. It delivers combined anti‑inflammatory and bronchodilator effects for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and adolescents.

GNH USA supplies Innovair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for respiratory therapeutics.

Innovair is an inhaled combination therapy that targets airway inflammation and bronchoconstriction in chronic respiratory disease. - Asthma: provides long‑term control of symptoms and reduces the risk of severe attacks. - Chronic obstructive pulmonary disease (COPD): improves airflow limitation and decreases the frequency of exacerbations. - Patients requiring combined inhaled corticosteroid and long‑acting β2‑agonist therapy: offers convenient once‑daily maintenance dosing.

Innovair may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Throat irritation or soreness - Hoarseness or voice change - Cough after inhalation - Oral candidiasis (thrush)

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Cardiovascular effects such as tachycardia or palpitations

Before prescribing Innovair, clinicians should consider several safety aspects. - Assess infection risk: avoid initiating during active respiratory infections. - Monitor growth in children: schedule periodic height and weight assessments. - Ensure correct inhaler technique: educate patients on priming and breath‑hold. - Avoid abrupt discontinuation: may lead to loss of asthma control. - Store at room temperature below 25°C: keep in the original pack, protect from moisture and heat.

Innovair can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise systemic corticosteroid levels.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance the risk of hypokalemia when combined with β2‑agonists. - Theophylline: concurrent use may increase the likelihood of cardiac arrhythmias. - Other inhaled corticosteroids: combined use may increase systemic steroid exposure.